Europe joins Avastin breast cancer review

European regulators are reviewing the benefits of using Roche's (ROG.VX) top-selling Avastin drug in breast cancer, in light of fresh clinical trial results; the review comes as FDA is also reconsidering the indication. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.